SCYNEXIS (SCYX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Apr, 2026Executive summary
Annual meeting scheduled for June 25, 2026, to be held virtually, with six key proposals up for shareholder vote, including director elections, auditor ratification, executive compensation, equity plan amendment, and capital structure changes.
Shareholders of record as of April 27, 2026, are eligible to vote; voting can be done online, by phone, or by mail.
Board recommends voting FOR all director nominees, FOR all proposals, and for ONE YEAR frequency on say-on-pay votes.
Voting matters and shareholder proposals
Election of six directors to serve until the 2027 annual meeting.
Ratification of Deloitte & Touche LLP as independent auditor for fiscal year 2026.
Advisory vote on executive compensation (say-on-pay) and on the frequency of future say-on-pay votes (Board recommends annual votes).
Approval of an amendment to the 2024 Equity Incentive Plan to increase authorized shares by 9,600,000.
Approval of an amendment to the Certificate of Incorporation to increase authorized common stock to either 60,000,000 (if reverse split is approved) or 300,000,000.
Shareholder proposals for the 2027 meeting must be submitted by December 31, 2026, for inclusion in proxy materials.
Board of directors and corporate governance
Board will be reduced to six members following the retirement of one director.
43% of directors are women or racially/ethnically diverse.
All directors except the CEO are independent under Nasdaq standards.
Board committees: Audit, Compensation, and Nominating & Corporate Governance, all with independent members.
Board leadership structure separates Chairman and CEO roles.
Latest events from SCYNEXIS
- Resale registration for 87M shares from a private placement; proceeds only from warrant exercises.SCYX
Registration filing1 May 2026 - Key votes include board elections, auditor ratification, and major share authorization changes.SCYX
Proxy filing1 May 2026 - Shareholders will vote on a reverse stock split to help maintain Nasdaq listing compliance.SCYX
Proxy filing27 Apr 2026 - Shareholders will vote on director elections, compensation, equity plan, and capital structure changes.SCYX
Proxy filing20 Apr 2026 - Shareholders will vote on a reverse stock split to help maintain Nasdaq listing compliance.SCYX
Proxy filing17 Apr 2026 - Acquisition of SCY-770 for ADPKD offers major commercial potential and no royalty obligations.SCYX
M&A announcement2 Apr 2026 - SCY-247 advances as a potent antifungal with strong clinical data and significant market potential.SCYX
investor presentation4 Mar 2026 - 2025 revenue rose sharply on GSK deals; SCY-247 clinical progress and cash runway extended.SCYX
Q4 20254 Mar 2026 - Advancing next-gen antifungal SCY-247 and expanding GSK partnership, with strong financials.SCYX
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026